Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won ...

Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...

German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...

October 08, 2024 I Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Boehringer Ingelheim and Circle Pharma have entered ... The latest deal will strengthen the oncology pipeline of Boehringer, which includes a range of cancer cell-directed and immuno-oncology ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif., October 09, 2024--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...